Co-delivery of doxorubicin and siRNA using octreotide-conjugated gold nanorods for targeted neuroendocrine cancer therapy.
about
Nanoparticle ligand presentation for targeting solid tumorsA Light-Driven Therapy of Pancreatic Adenocarcinoma Using Gold Nanorods-Based Nanocarriers for Co-Delivery of Doxorubicin and siRNACo-delivery of doxorubicin and SATB1 shRNA by thermosensitive magnetic cationic liposomes for gastric cancer therapyMultifunctional gold nanorods for siRNA gene silencing and photothermal therapy.Conjugated polymer and drug co-encapsulated nanoparticles for chemo- and photo-thermal combination therapy with two-photon regulated fast drug release.Reversal of multidrug resistance in MCF-7/Adr cells by codelivery of doxorubicin and BCL2 siRNA using a folic acid-conjugated polyethylenimine hydroxypropyl-β-cyclodextrin nanocarrierPharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance.Thailandepsin A-loaded and octreotide-functionalized unimolecular micelles for targeted neuroendocrine cancer therapy.Nanomaterials as Non-viral siRNA Delivery Agents for Cancer Therapy.Multifunctional selenium nanoparticles as carriers of HSP70 siRNA to induce apoptosis of HepG2 cells.A RNA nanotechnology platform for a simultaneous two-in-one siRNA delivery and its application in synergistic RNAi therapy.Octreotide-functionalized and resveratrol-loaded unimolecular micelles for targeted neuroendocrine cancer therapy.Anti-metastatic potential of somatostatin analog SOM230: Indirect pharmacological targeting of pancreatic cancer-associated fibroblasts.Recent advances in delivery of drug-nucleic acid combinations for cancer treatmentpH-sensitive drug-delivery systems for tumor targeting.Nanoscale particulate systems for multidrug delivery: towards improved combination chemotherapy.pH-responsive drug-delivery systems.Nanocarriers for delivery of siRNA and co-delivery of siRNA and other therapeutic agents.Integrin-targeted pH-responsive micelles for enhanced efficiency of anticancer treatment in vitro and in vivo.Polysaccharide nano-vesicular multidrug carriers for synergistic killing of cancer cells.Magnetic core-shell nanocapsules with dual-targeting capabilities and co-delivery of multiple drugs to treat brain gliomas.Multifunctional pH-sensitive polymeric nanoparticles for theranostics evaluated experimentally in cancer.Polymers in the Co-delivery of siRNA and Anticancer Drugs for the Treatment of Drug-resistant Cancers.Combinatorial therapeutic approaches with RNAi and anticancer drugs using nanodrug delivery systems.Nanoformulations for combination or cascade anticancer therapy.KE108-conjugated unimolecular micelles loaded with a novel HDAC inhibitor thailandepsin-A for targeted neuroendocrine cancer therapy.PEGylated gold nanorod separation based on aspect ratio: characterization by asymmetric-flow field flow fractionation with UV-Vis detection.AB3-Loaded and Tumor-Targeted Unimolecular Micelles for Medullary Thyroid Cancer Treatment.Co-delivery nanoparticles of anti-cancer drugs for improving chemotherapy efficacy.Fabrication of self-assembled folate-biotin-quaternized starch nanoparticles as co-carrier of doxorubicin and siRNA.CDC20siRNA and paclitaxel co-loaded nanometric liposomes of a nipecotic acid-derived cationic amphiphile inhibit xenografted neuroblastoma.The generation of compartmentalized nanoparticles containing siRNA and cisplatin using a multi-needle electrohydrodynamic strategy.Engineering functional inorganic-organic hybrid systems: advances in siRNA therapeutics.EGFP-Based Protein Nanoparticles with Cell-Penetrating Peptide for Efficient siRNA Delivery.
P2860
Q27009522-B0FA5D92-F90C-46B7-BB58-B8640A85A239Q28394647-D1A0ECD8-1D8E-4E0E-87B3-A15D153433CAQ28541628-B57F8984-8E90-482B-95B4-FA900EA4DDC7Q34276290-98668D46-1418-4411-9280-8238E3B3DE51Q35546710-83A2F230-C5F7-4C19-BBFC-F5BF55AA1DBFQ35546832-FA39E457-F1B2-418C-AE31-0AD2029095BEQ35695360-6CC593F1-C2B4-46F8-A295-D0FD57BD2EB7Q35963760-DD5877EA-DEF6-4EF4-B1AD-A27C93D3DD99Q37020672-CB6FDAC7-EDF0-4CBB-A031-607C14840F72Q37082794-3D2B70DF-B0D3-41A1-A91A-9D227475359EQ37209072-9BFF438D-295F-4E98-8758-AF2B55DD210AQ37403020-FFEE785F-728C-4EAD-B55A-B08285C8C4C6Q37520300-B6C75BCE-2E3D-4CE7-9E1B-A8A27B933A0AQ38102522-FD4183FC-06EA-45A9-AE07-7F76CFEDFBD6Q38168593-DD35200B-E35A-4647-8034-2FDD190760FBQ38183852-0F8FFFF8-E3B2-4AE3-8B43-73DDCA872E46Q38258883-A177FA8A-6F58-431B-B26C-97B97D897981Q38555082-B4661E43-2AC3-4A7E-9593-20A980AB59A9Q38562389-4C9AF9EC-0C58-4DE0-BDF8-EAE817CFF8BAQ38961730-D44D3CBC-4F3F-477C-9FF0-5F8C8F155250Q39016049-AC2C688B-B3EB-49B6-90D8-3105D6BE9DFBQ39026821-F87531B4-BF72-4D40-AC09-74F72E606CCCQ39125540-8C7E8DC6-9CC8-40E8-A570-F9FDB473EE5EQ39317565-CF53D7E5-5439-47DE-8EB0-3F23368F1E97Q39380111-5114BD70-0EB4-4FCE-8F1A-B75A93DF8EFDQ42176778-F24E2B8E-C0FF-4CD5-821D-912A0D7848F7Q45188945-30CF3E3B-C5B9-42FF-9681-BAAA106A124FQ47175904-93C77751-D7CC-4A5A-ABDE-516DE4F64FE7Q47808831-C697E252-1019-4607-990E-09C509C96919Q47875471-A38D06A7-F0D2-43AE-B062-10D3B1369DA4Q48101540-C9EB8B78-0756-420E-B4CB-4C03E1EBE6E5Q48235071-5FC2F722-C22A-47E4-A339-9D886549109EQ50123721-FCD24DD2-93B0-4E01-82E3-44C867978D88Q50264867-EF64544C-6E7D-4F08-9499-0586ECA2780A
P2860
Co-delivery of doxorubicin and siRNA using octreotide-conjugated gold nanorods for targeted neuroendocrine cancer therapy.
description
2012 nî lūn-bûn
@nan
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Co-delivery of doxorubicin and ...... neuroendocrine cancer therapy.
@ast
Co-delivery of doxorubicin and ...... neuroendocrine cancer therapy.
@en
Co-delivery of doxorubicin and ...... neuroendocrine cancer therapy.
@nl
type
label
Co-delivery of doxorubicin and ...... neuroendocrine cancer therapy.
@ast
Co-delivery of doxorubicin and ...... neuroendocrine cancer therapy.
@en
Co-delivery of doxorubicin and ...... neuroendocrine cancer therapy.
@nl
prefLabel
Co-delivery of doxorubicin and ...... neuroendocrine cancer therapy.
@ast
Co-delivery of doxorubicin and ...... neuroendocrine cancer therapy.
@en
Co-delivery of doxorubicin and ...... neuroendocrine cancer therapy.
@nl
P2093
P2860
P356
P1433
P1476
Co-delivery of doxorubicin and ...... neuroendocrine cancer therapy
@en
P2093
Ajitha Dammalapati
Alireza Javadi
Herbert Chen
Jacob Eide
Renata Jaskula-Sztul
Shaoqin Gong
Yuling Xiao
P2860
P304
P356
10.1039/C2NR31853A
P407
P577
2012-11-01T00:00:00Z